贝那利珠单抗快速起效的有力证据。 - Suppr

Robust evidence of the rapid efficacy of benralizumab.

作者信息

Nagano Tatsuya

机构信息

Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

出版信息

J Thorac Dis. 2025 Jul 31;17(7):4376-4378. doi: 10.21037/jtd-2025-452. Epub 2025 Jul 29.

DOI:10.21037/jtd-2025-452

PMID:40809210

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12340284/

Abstract

摘要

相似文献

Robust evidence of the rapid efficacy of benralizumab.

J Thorac Dis. 2025 Jul 31;17(7):4376-4378. doi: 10.21037/jtd-2025-452. Epub 2025 Jul 29.

Anti-IL-5 therapies for asthma.

Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD010834. doi: 10.1002/14651858.CD010834.pub4.

Anti-IL5 therapies for asthma.

Cochrane Database Syst Rev. 2017 Sep 21;9(9):CD010834. doi: 10.1002/14651858.CD010834.pub3.

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.

Lancet Respir Med. 2025 Jan;13(1):59-68. doi: 10.1016/S2213-2600(24)00299-6. Epub 2024 Nov 29.

Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.

J Allergy Clin Immunol. 2022 Nov;150(5):1097-1105.e12. doi: 10.1016/j.jaci.2022.05.024. Epub 2022 Jun 27.

Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.

J Allergy Clin Immunol. 2023 Mar;151(3):747-755. doi: 10.1016/j.jaci.2022.11.021. Epub 2022 Dec 17.

Population Pharmacokinetics and Exposure-Response Analysis of Benralizumab in Chinese Adults, Adolescents, and Pediatric Participants with Severe Eosinophilic Asthma.

Clin Pharmacokinet. 2025 Jun 23. doi: 10.1007/s40262-025-01538-9.

Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.

Adv Ther. 2020 Feb;37(2):718-729. doi: 10.1007/s12325-019-01191-2. Epub 2019 Dec 14.

Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction.

Clin Exp Allergy. 2025 Jul;55(7):521-531. doi: 10.1111/cea.70083. Epub 2025 May 30.

Rapid effect of benralizumab in fulminant eosinophilic myocarditis in the setting of uncontrolled eosinophilic asthma.

J Cardiol Cases. 2023 Jun 14;28(3):100-104. doi: 10.1016/j.jccase.2023.04.012. eCollection 2023 Sep.

本文引用的文献

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.

Lancet Respir Med. 2025 Jan;13(1):59-68. doi: 10.1016/S2213-2600(24)00299-6. Epub 2024 Nov 29.

Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.

Eur Respir J. 2022 Mar 3;59(3). doi: 10.1183/13993003.04306-2020. Print 2022 Mar.

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.

Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22.

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma.

Am J Respir Crit Care Med. 2020 Nov 1;202(9):1314-1316. doi: 10.1164/rccm.202003-0729LE.

The Use of Benralizumab in the Treatment of Near-Fatal Asthma: A New Approach.

Am J Respir Crit Care Med. 2020 Jun 1;201(11):1441-1443. doi: 10.1164/rccm.202001-0093LE.

Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma.

Ann Allergy Asthma Immunol. 2019 May;122(5):478-485. doi: 10.1016/j.anai.2019.02.016. Epub 2019 Feb 23.

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma.

Clin Pharmacol Ther. 2019 Aug;106(2):383-390. doi: 10.1002/cpt.1371. Epub 2019 Mar 22.

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.

N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22.

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.

Lancet. 2016 Oct 29;388(10056):2115-2127. doi: 10.1016/S0140-6736(16)31324-1. Epub 2016 Sep 5.

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.

Lancet. 2016 Oct 29;388(10056):2128-2141. doi: 10.1016/S0140-6736(16)31322-8. Epub 2016 Sep 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Robust evidence of the rapid efficacy of benralizumab.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献